Immunologic Effects of Levamisole in Mice and Humans: Evidence for Augmented Antibody Response Without Modulation of Cellular Cytotoxicity

M. A. Tempero, Y. Haga, C. Sivinski, D. Birt, Lynell Warren Klassen, Geoffrey Milton Thiele

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Selected immunomodulatory effects of levamisole were studied in patients with asymptomatic metastatic colon cancer and in a preclinical model (CF1 female mice treated with methyl-azoxymethanol acetate) for colon tumors. In the patient population studied, there was no augmentation of cellular cytotoxicity or alteration in lymphocyte subpopulations that participate in these functions. An increase in Fc receptor binding on circulating monocytes was apparent at the 4-week timepoint; however, a corresponding increase in antibody-dependent cellular cytotoxicity was observed in only one of the six patients studied. In most patients, cellular cytotoxicity diminished with time. No significant effects on cellular immunity or carcinogenesis were observed in our murine studies. However, treatment with levamisole did increase circulating immunoglobulin levels and IgM response in mice immunized with the T-dependent antigen keyhole limpet hemocyanin. This parameter was not tested in the human trial. Failure to demonstrate antitumor effects on cellular immunity by levamisole in both human and murine studies suggests that these effects, if they do exist, may involve immunological parameters that were not tested using our methods or that may not be apparent in patients with more advanced malignancy.

Original languageEnglish (US)
Pages (from-to)47-57
Number of pages11
JournalJournal of Immunotherapy
Volume17
Issue number1
DOIs
StatePublished - Jan 1995

Fingerprint

Levamisole
Antibody Formation
Cellular Immunity
Fc Receptors
Viral Tumor Antigens
Lymphocyte Subsets
Colonic Neoplasms
Immunoglobulin M
Immunoglobulins
Monocytes
Neoplasms
Colon
Carcinogenesis
Antibodies
Population

Keywords

  • Colon cancer
  • Immunomodulation.
  • Levamisole

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Immunologic Effects of Levamisole in Mice and Humans : Evidence for Augmented Antibody Response Without Modulation of Cellular Cytotoxicity. / Tempero, M. A.; Haga, Y.; Sivinski, C.; Birt, D.; Klassen, Lynell Warren; Thiele, Geoffrey Milton.

In: Journal of Immunotherapy, Vol. 17, No. 1, 01.1995, p. 47-57.

Research output: Contribution to journalArticle

@article{1eef9574689347e5bde246b74470da8a,
title = "Immunologic Effects of Levamisole in Mice and Humans: Evidence for Augmented Antibody Response Without Modulation of Cellular Cytotoxicity",
abstract = "Selected immunomodulatory effects of levamisole were studied in patients with asymptomatic metastatic colon cancer and in a preclinical model (CF1 female mice treated with methyl-azoxymethanol acetate) for colon tumors. In the patient population studied, there was no augmentation of cellular cytotoxicity or alteration in lymphocyte subpopulations that participate in these functions. An increase in Fc receptor binding on circulating monocytes was apparent at the 4-week timepoint; however, a corresponding increase in antibody-dependent cellular cytotoxicity was observed in only one of the six patients studied. In most patients, cellular cytotoxicity diminished with time. No significant effects on cellular immunity or carcinogenesis were observed in our murine studies. However, treatment with levamisole did increase circulating immunoglobulin levels and IgM response in mice immunized with the T-dependent antigen keyhole limpet hemocyanin. This parameter was not tested in the human trial. Failure to demonstrate antitumor effects on cellular immunity by levamisole in both human and murine studies suggests that these effects, if they do exist, may involve immunological parameters that were not tested using our methods or that may not be apparent in patients with more advanced malignancy.",
keywords = "Colon cancer, Immunomodulation., Levamisole",
author = "Tempero, {M. A.} and Y. Haga and C. Sivinski and D. Birt and Klassen, {Lynell Warren} and Thiele, {Geoffrey Milton}",
year = "1995",
month = "1",
doi = "10.1097/00002371-199501000-00006",
language = "English (US)",
volume = "17",
pages = "47--57",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Immunologic Effects of Levamisole in Mice and Humans

T2 - Evidence for Augmented Antibody Response Without Modulation of Cellular Cytotoxicity

AU - Tempero, M. A.

AU - Haga, Y.

AU - Sivinski, C.

AU - Birt, D.

AU - Klassen, Lynell Warren

AU - Thiele, Geoffrey Milton

PY - 1995/1

Y1 - 1995/1

N2 - Selected immunomodulatory effects of levamisole were studied in patients with asymptomatic metastatic colon cancer and in a preclinical model (CF1 female mice treated with methyl-azoxymethanol acetate) for colon tumors. In the patient population studied, there was no augmentation of cellular cytotoxicity or alteration in lymphocyte subpopulations that participate in these functions. An increase in Fc receptor binding on circulating monocytes was apparent at the 4-week timepoint; however, a corresponding increase in antibody-dependent cellular cytotoxicity was observed in only one of the six patients studied. In most patients, cellular cytotoxicity diminished with time. No significant effects on cellular immunity or carcinogenesis were observed in our murine studies. However, treatment with levamisole did increase circulating immunoglobulin levels and IgM response in mice immunized with the T-dependent antigen keyhole limpet hemocyanin. This parameter was not tested in the human trial. Failure to demonstrate antitumor effects on cellular immunity by levamisole in both human and murine studies suggests that these effects, if they do exist, may involve immunological parameters that were not tested using our methods or that may not be apparent in patients with more advanced malignancy.

AB - Selected immunomodulatory effects of levamisole were studied in patients with asymptomatic metastatic colon cancer and in a preclinical model (CF1 female mice treated with methyl-azoxymethanol acetate) for colon tumors. In the patient population studied, there was no augmentation of cellular cytotoxicity or alteration in lymphocyte subpopulations that participate in these functions. An increase in Fc receptor binding on circulating monocytes was apparent at the 4-week timepoint; however, a corresponding increase in antibody-dependent cellular cytotoxicity was observed in only one of the six patients studied. In most patients, cellular cytotoxicity diminished with time. No significant effects on cellular immunity or carcinogenesis were observed in our murine studies. However, treatment with levamisole did increase circulating immunoglobulin levels and IgM response in mice immunized with the T-dependent antigen keyhole limpet hemocyanin. This parameter was not tested in the human trial. Failure to demonstrate antitumor effects on cellular immunity by levamisole in both human and murine studies suggests that these effects, if they do exist, may involve immunological parameters that were not tested using our methods or that may not be apparent in patients with more advanced malignancy.

KW - Colon cancer

KW - Immunomodulation.

KW - Levamisole

UR - http://www.scopus.com/inward/record.url?scp=0028985214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028985214&partnerID=8YFLogxK

U2 - 10.1097/00002371-199501000-00006

DO - 10.1097/00002371-199501000-00006

M3 - Article

C2 - 7728305

AN - SCOPUS:0028985214

VL - 17

SP - 47

EP - 57

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 1

ER -